- Entheon Biomedical (ENBI) announces enrollment in Phase 1 Study of DMT
- The first patient has been admitted into the clinic for observation and preliminary testing, with dosing to occur the following day
- After dosing, the patient will remain in the clinic overnight for evaluation and monitoring
- The EBRX-101 study is the core research focus of Entheon Rx™, which is focused on advancing the therapeutic potential of DMT-based drug analogues
- The study will use an adaptive, randomized, double-blind, placebo-controlled design with a single ascending dose of intravenous DMT
- Entheon Biomedical Corp. (ENBI) is in the grey, trading at C$0.18 at 12:26 pm EST
Entheon Biomedical’s (ENBI) first patient has been enrolled in the EBRX-101 study.
This is a comprehensive phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of N, N-dimethyltryptamine (DMT).
The company enrolled the first EBRX-101 study patient following successful site initiation and patient recruitment.
The first patient has been admitted into the [research] clinic for observation and preliminary testing, with dosing to occur the following day.
After dosing, the patient will remain in the clinic overnight for evaluation and monitoring.
Recruitment and screening of additional study participants continue, and the company expects full enrollment of its first study cohort in short order.
“The enrollment and imminent dosing of the first patient in Entheon’s Phase 1 study of DMT begins the active research phase of Entheon’s core clinical program,” said Timothy Ko, Chief Executive Officer of Entheon.
“In our view, this is a monumental occasion, marking the start of the formal clinical stage of Entheon’s development of DMT as a treatment for addiction disorders,” added Ko.
The EBRX-101 study is the core research focus of Entheon Rx™, one of its business divisions, which is focused on advancing the therapeutic potential of DMT and DMT-based drug analogues.
The study will use an adaptive, randomized, double-blind, placebo-controlled design with a single ascending dose of intravenous DMT to be administered via continuous-controlled infusion to a population of otherwise healthy smokers.
This phase 1 study will provide Entheon with essential safety and dosing data, providing the foundation for further research of DMT’s therapeutic potential. The study is conducted at the Centre for Human Drug Research in Leiden, the Netherlands.
Entheon is a biomedical company focused on researching and developing psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders.
Entheon intends to generate revenue by selling its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
Entheon Biomedical Corp. (ENBI) is in the grey, trading at C$0.18 at 12:26 pm EST.
